Comparative Pharmacology
Head-to-head clinical analysis: GYNE LOTRIMIN 3 versus TERAZOL 3.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GYNE LOTRIMIN 3 versus TERAZOL 3.
GYNE-LOTRIMIN 3 vs TERAZOL 3
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clotrimazole, an imidazole antifungal, inhibits fungal cytochrome P450 14α-demethylase, disrupting ergosterol synthesis and increasing membrane permeability.
Terconazole is an azole antifungal agent that inhibits fungal cytochrome P450 14α-demethylase, thereby blocking the conversion of lanosterol to ergosterol, an essential component of the fungal cell membrane. This disrupts membrane integrity and leads to fungal cell death.
Intravaginal: one applicatorful (5 g of 2% cream) or one suppository (200 mg) once daily at bedtime for 3 days.
One applicatorful (approximately 5 g of 0.8% terconazole vaginal cream) intravaginally once daily at bedtime for 3 consecutive days.
None Documented
None Documented
Terminal elimination half-life is 3.5–5 hours for topical administration; systemic absorption is minimal (<0.5%), so half-life reflects local clearance.
The terminal elimination half-life after intravaginal application is approximately 4-6 hours, reflecting local retention and slow systemic absorption of the small absorbed fraction.
Clotrimazole is primarily excreted via feces (biliary elimination) as metabolites, with approximately 0.5% excreted renally as unchanged drug.
Following intravaginal administration, terconazole is minimally absorbed (<5%) into systemic circulation. Absorbed drug is primarily metabolized in the liver and excreted via feces (approximately 50-60% as metabolites) and urine (approximately 20-30% as metabolites). Unabsorbed drug is excreted in feces.
Category C
Category C
Azole Antifungal
Azole Antifungal